UNIVERSITY OF CALIFORNIA, IRVINE
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1965-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.uci.edu
Clinical Trials
452
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (322 trials with phase data)• Click on a phase to view related trials
Telemedicine to Support Living Kidney Donor Candidates
- Conditions
- HealthyLiving Kidney Donation
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 70
- Registration Number
- NCT07206069
- Locations
- 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
Sling-Fiber Preservation POEM vs. Conventional POEM for Reducing Post-POEM GERD: A Randomized Control Trial
- Conditions
- Achalasia, EsophagealGERD (Gastroesophageal Reflux Disease)
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 120
- Registration Number
- NCT07178821
- Locations
- 🇺🇸
University of California, Irvine - UCI Medical Center, Orange, California, United States
Resilience in Reentry: Cognitive-Behavioral Resilience Training for Parolees With Adjustment Challenges
- Conditions
- Adjustment
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 60
- Registration Number
- NCT07167719
Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound
- Conditions
- PreeclampsiaPreeclampsia PostpartumPreeclampsia Severe or Mild
- Interventions
- Diagnostic Test: Butterfly iQ3 ultrasound system for determination of postpartum volume status
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 96
- Registration Number
- NCT07167862
- Locations
- 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures
- Conditions
- Rib Fractures
- Interventions
- Drug: Suzetrigine (SUZ)Drug: Placebo
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 80
- Registration Number
- NCT07145346
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 91
- Next
News
FDA Approves First Liquid Embolic System for Hypervascular Tumor Treatment
The FDA has granted premarket approval to the Embrace Hydrogel Embolic System, marking the first liquid embolic specifically approved for hypervascular tumor embolization based on randomized controlled trial data.
Engineered Microglia: A Revolutionary Approach to Treating Alzheimer's Disease
UC Irvine researchers have developed a groundbreaking therapy using CRISPR-edited microglia that can detect and target amyloid plaques in Alzheimer's disease, delivering therapeutic proteins precisely where needed.
INSPIRE Trials: Computerized Alerts Improve Antibiotic Selection in Hospitalized Patients by Up to 35%
• NIH-funded clinical trials involving over 316,000 patients across 92 hospitals demonstrate that computerized alerts can improve appropriate antibiotic selection by 35% for abdominal infections and 28% for skin and soft tissue infections. • The INSPIRE trials used patient-specific data to identify individuals at low risk for antibiotic-resistant infections, prompting physicians to switch from broad-spectrum to standard antibiotics when appropriate. • Researchers from UC Irvine, Harvard Pilgrim Health Care Institute, and HCA Healthcare collaborated on the studies, which could significantly reduce antibiotic resistance and improve patient outcomes nationwide.